Börse Express - Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus

due to Progressive Familial Intrahepatic Cholestasis (PFIC)Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuro...

Related Keywords

Israel ,United States ,Belgium ,Italy ,France ,Germany ,Canada ,Toronto ,Ontario ,Canadians ,Canadian ,America ,Intrahepatic Cholestasis ,Medison Pharma ,Binita Kamath ,Gil Gurfinkel ,Stewart Campbell ,Ipsen Euronext ,Walter Perez ,Division Head ,Resource Network ,Health Canada ,Progressive Familial Intrahepatic Cholestasis ,Executive Vice President ,North America ,Sick Children ,Serious Warnings ,Wirtschaft ,